🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

672 results for “Nan” Clear

  1. locally manufactured adoptive cellular therapy (ACT) product

    Iovance Biotherapeutics B.V.

    Malignant Pleural Effusion

    phase 1 mab active

    1 trial

  2. mPEG-r-crisantaspase

    Jazz Pharmaceuticals Ireland Limited

    Hematologic Malignancies

    phase 1 mab completed

    1 trial

  3. omacetaxine mepesuccinate

    Teva Pharma GmbH

    Hematologic Malignancies

    phase 1 small molecule completed

    1 trial

  4. ombrabulin (AVE8062)

    Sanofi Pasteur

    Neoplasms, Malignant

    phase 1 small molecule completed

    1 trial

  5. palifosfamide-tris

    Alaunos Therapeutics

    Malignancy

    phase 1 small molecule active

    1 trial

  6. rQNestin

    Candel Therapeutics

    Malignant Glioma of Brain

    phase 1 small molecule active

    1 trial

  7. recombinant adenovirus containing the ornithine transcarbamylase gene

    Ultragenyx UK Limited

    Ornithine Transcarbamylase Deficiency Disease

    phase 1 gene therapy terminated

    1 trial

  8. recombinant human thrombopoietin injection

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Liver Disease Chronic

    phase 1 small molecule active

    1 trial

  9. zelicapavir (therapeutic dose)

    ENANTA PHARMACEUTICALS INC

    RSV Infection

    phase 1 small molecule completed

    1 trial

  10. 0.1% bupivacaine

    United Therapeutics Europe Ltd

    Pregnancy

    approved small molecule active

    1 trial

  11. 20 µg recombinant hepatitis B vaccine at months 0, 1, and 6

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Hepatitis B Vaccine

    approved mab active

    3 trials

  12. Abrysvo powder and solvent for solution for injection Respiratory syncytial virus vaccine (bivalent, recombinant)

    Pfizer Australia Pty Ltd

    RSV-infection

    approved small molecule active

    1 trial

  13. Alcohol injection

    The University of Hong Kong

    Malignancy

    approved small molecule active

    1 trial

  14. Aldurazyme (Recombinant Human Alpha-L-Iduronidase)

    BioMarin Pharmaceutical Australia Pty Ltd

    Mucopolysaccharidosis I

    approved mab completed

    3 trials

  15. Antihemophilic Factor (Recombinant) - Plasma/Albumin Free Method

    Takeda

    Hemophilia A

    approved mab completed

    4 trials

  16. Antihemophilic factor, recombinant, manufactured protein-free

    Takeda

    Hemophilia A

    approved small molecule completed

    6 trials

  17. Arexvy powder and suspension for suspension for injection Respiratory Syncytial Virus (RSV) vaccine (recombinant, adjuvanted)

    GlaxoSmithKline

    Respiratory Syncytial Virus Infections

    approved small molecule active

    1 trial

  18. Aspirin

    The First People's Hospital of Lianyungang

    Recurrent Pregnancy Loss

    approved small molecule active

    1 trial

  19. BIMERVAX LP.8.1 emulsion for injection COVID-19 Vaccine (recombinant, adjuvanted)

    Hipra Human Health S.L.

    COVID-19

    approved small molecule active

    1 trial

  20. BIMERVAX LP.8.1 emulsion for injection COVID-19 Vaccine (recombinant, adjuvanted), Spikevax bivalent Original/Omicron BA.1 25 micrograms/25 micrograms dispersion for injection COVID 19 mRNA Vaccine, Comirnaty 30 micrograms/dose dispersion for injection COVID-19 mRNA Vaccine, Spikevax 50 micrograms dispersion for injection in pre-filled syringe COVID-19 mRNA Vaccine, Comirnaty JN.1 30 micrograms/dose dispersion for injection in pre-filled syringe COVID-19 mRNA Vaccine, Nuvaxovid dispersion for injection COVI

    The George Institute

    COVID-19 infection

    approved small molecule active

    1 trial

  21. Behavioral: Buprenorphine/naloxone maintenance (Mtn)

    BRIGHT MINDS BIOSCIENCES INC.

    Opiate Dependence

    approved other completed

    1 trial

  22. Cohort A will receive an initial load dose of 8mg/kg and a maintenance dose of 6mg/kg intravenously on the first day of every three weeks for a total of 4 doses

    The First People's Hospital of Lianyungang

    HER2 Positive Breast Cancer

    approved small molecule active

    1 trial

  23. Comirnaty 30 micrograms/dose dispersion for injection COVID-19 mRNA Vaccine, Spikevax 0.2 mg/mL dispersion for injection COVID-19 mRNA Vaccine, EVUSHELD 150 mg + 150 mg solution for injection, Xevudy 500 mg concentrate for solution for infusion, Nuvaxovid dispersion for injection COVID-19 Vaccine (recombinant, adjuvanted)

    The George Institute

    Covid-19 infection

    approved small molecule active

    1 trial

  24. Commercial Hylenex® recombinant (hyaluronidase human injection)

    HALOZYME THERAPEUTICS, INC.

    Type 1 Diabetes Mellitus

    approved small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources